Compare Stocks: MDWD, SVA, SGMT, and RGNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDWD MediWound	$13.29	$14.00	$12.52 ▼ $20.30	$170.78M	0.14	96,664 shs	86,155 shs
RGNX REGENXBIO	$8.94	$11.01	$5.45 ▼ $16.19	$590.13M	0.94	1.27 million shs	1.07 million shs
SGMT Sagimet Biosciences	$10.94	$8.68	$4.50 ▼ $11.24	$680.03M	3.45	1.24 million shs	1.25 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.8	N/A	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDWD MediWound	0.00%	+4.98%	-7.64%	-6.47%	-18.42%
RGNX REGENXBIO	0.00%	-7.45%	-16.60%	+45.84%	-7.93%
SGMT Sagimet Biosciences	0.00%	+3.70%	+20.75%	+67.53%	+53.87%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDWD MediWound	$13.29	$14.00	$12.52 ▼ $20.30	$170.78M	0.14	96,664 shs	86,155 shs
RGNX REGENXBIO	$8.94	$11.01	$5.45 ▼ $16.19	$590.13M	0.94	1.27 million shs	1.07 million shs
SGMT Sagimet Biosciences	$10.94	$8.68	$4.50 ▼ $11.24	$680.03M	3.45	1.24 million shs	1.25 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.8	N/A	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDWD MediWound	0.00%	+4.98%	-7.64%	-6.47%	-18.42%
RGNX REGENXBIO	0.00%	-7.45%	-16.60%	+45.84%	-7.93%
SGMT Sagimet Biosciences	0.00%	+3.70%	+20.75%	+67.53%	+53.87%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDWD MediWound	2.25	Hold	$33.00	148.31% Upside
RGNX REGENXBIO	2.62	Moderate Buy	$23.27	160.32% Upside
SGMT Sagimet Biosciences	2.60	Moderate Buy	$29.17	166.61% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MDWD, SVA, SGMT, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$23.00 ➝ $21.00
8/25/2026	RGNX REGENXBIO	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$32.00 ➝ $29.00
8/25/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
8/14/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
8/14/2026	SGMT Sagimet Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/14/2026	SGMT Sagimet Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$12.00 ➝ $29.00
8/12/2026	RGNX REGENXBIO	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$49.00 ➝ $56.00
8/10/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$26.00 ➝ $23.00
8/7/2026	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$18.00
8/7/2026	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Hold

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDWD MediWound	$16.96M	10.07	N/A	N/A	$3.40 per share	3.91
RGNX REGENXBIO	$170.44M	3.46	N/A	N/A	$2.03 per share	4.40
SGMT Sagimet Biosciences	$2M	340.02	N/A	N/A	$3.42 per share	3.20
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDWD MediWound	-$23.88M	-$1.80	N/A	N/A	N/A	-170.10%	-47.24%	-24.27%	11/19/2026 (Estimated)
RGNX REGENXBIO	-$193.88M	-$3.79	N/A	N/A	N/A	-112.58%	-220.07%	-46.04%	11/5/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MDWD, SVA, SGMT, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MDWD MediWound	-$0.7617	-$0.77	-$0.0083	-$0.77	$2.59 million	$3.09 million
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/6/2026	Q2 2026	RGNX REGENXBIO	$0.0787	$0.43	+$0.3513	$0.43	$97.63 million	$108.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDWD MediWound	N/A	2.32	2.09
RGNX REGENXBIO	N/A	2.86	2.86
SGMT Sagimet Biosciences	N/A	45.03	45.02
SVA Sinovac Biotech	0.04	6.07	5.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDWD MediWound	46.83%
RGNX REGENXBIO	88.08%
SGMT Sagimet Biosciences	87.86%
SVA Sinovac Biotech	N/A

Insider Ownership

Company	Insider Ownership
MDWD MediWound	9.20%
RGNX REGENXBIO	14.22%
SGMT Sagimet Biosciences	11.50%
SVA Sinovac Biotech	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDWD MediWound	80	12.85 million	11.67 million	Optionable
RGNX REGENXBIO	370	66.01 million	56.63 million	Optionable
SGMT Sagimet Biosciences	8	62.16 million	55.01 million	Optionable
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable

MDWD, SVA, SGMT, and RGNX Headlines

Recent News About These Companies

Sinovac Biotech Corporate Event Calendar | NASDAQ:SVA

July 21, 2026 | benzinga.com

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

July 15, 2026 | businesswire.com

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

July 12, 2026 | businesswire.com

Sinovac Regains Nasdaq Listing Compliance After Filing Delayed Annual Report

June 15, 2026 | tipranks.com

Sinovac Biotech Ltd.

June 8, 2026 | edition.cnn.com

SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F

June 5, 2026 | businesswire.com

Sinovac Faces New Nasdaq Delisting Risk After Regaining Compliance

May 29, 2026 | tipranks.com

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

May 29, 2026 | businesswire.com

SVA Share News Today

May 16, 2026 | uk.investing.com

SINOVAC Reports Unaudited First Half of 2025 Financial Results

May 8, 2026 | businesswire.com

Sinovac Biotech Delays Key Annual 20-F Filing

April 30, 2026 | tipranks.com

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024

April 30, 2026 | businesswire.com

Clearwater Recovery Partners LLP Announces Cash Offer to Purchase Common Shares in Sinovac Biotech Ltd.

March 28, 2026 | tennessean.comT

Sinovac Controlling Shareholders Escape Investor Disclosure Suit

February 25, 2026 | news.bloomberglaw.comN

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

January 22, 2026 | businesswire.com

Sinovac Biotech receives Nasdaq notification regarding late filing of FY25

January 4, 2026 | msn.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | financialpost.comF

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

January 4, 2026 | businesswire.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | businesswire.com

Antigua High Court gives Sinovac Biotech board control until trial

December 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD, SVA, SGMT, and RGNX Company Descriptions

MediWound NASDAQ:MDWD

$13.29 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

REGENXBIO NASDAQ:RGNX

$8.94 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Sagimet Biosciences NASDAQ:SGMT

$10.94 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 09/4/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDWD, SVA, SGMT, and RGNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDWD, SVA, SGMT, and RGNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDWD, SVA, SGMT, and RGNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD, SVA, SGMT, and RGNX Company Descriptions

MediWound NASDAQ:MDWD

REGENXBIO NASDAQ:RGNX

Sagimet Biosciences NASDAQ:SGMT

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDWD, SVA, SGMT, and RGNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDWD, SVA, SGMT, and RGNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDWD, SVA, SGMT, and RGNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD, SVA, SGMT, and RGNX Company Descriptions

MediWound NASDAQ:MDWD

REGENXBIO NASDAQ:RGNX

Sagimet Biosciences NASDAQ:SGMT

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools